• Home
  • Search Results
  • High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome.

High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome.

Oncology reports (2015-06-18)
Hong-Jun Li, Qi-Man Sun, Long-Zi Liu, Jun Zhang, Jun Huang, Cheng-Hong Wang, Rui Ding, Kang Song, Zhong Tong

Interleukin-9 receptor (IL-9R) overexpression has a pivotal role in human hematological malignancies. However, the expression of IL-9R and its biological role in human solid tumors remains elusive. In the present study, western blot analysis and RT-qPCR were used to determine the expression of IL-9R in hepatocellular carcinoma (HCC) cell lines and tumor tissues. Proliferation, cell cycle, apoptosis and Transwell assays were used to examine the biological role of IL-9R in HCC cells. The results showed that IL-9R and its ligand IL-9 were constitutively expressed in HCC cells and tissues. Moreover, the expression levels of IL-9R and IL-9 were significantly higher in tumor tissues compared to the peritumor liver tissues. Functional experiments suggested that IL-9R significantly promoted HCC cell proliferation, invasion and inhibited apoptosis, possibly by acting through the IL-9/IL-9R axis. After silencing IL-9R, the expression of VEGF, p-p38, p-STAT3 and MMP9, markedly decreased suggesting the potential involvement of these molecules in IL-9R activity. Immunohistochemistry‑based survival analysis revealed that a differential expression of IL-9R in HCC tissue was a significant and independent prognostic factor for survival [HR, 1.66; 95% confidence interval (CI), 1.17-2.36; P=0.005] and recurrence [HR, 1.50; 95%CI, 1.04‑2.17; P=0.03]. In addition, a high IL-9R expression positively and significantly correlated with larger (P=0.012) and advanced tumor stage (P=0.018). The findings indicated that IL-9R was constitutively expressed and exerted a tumor-promoting effect in HCC, whose expression level may be a useful biomarker of tumor invasiveness and patient clinical outcome.

Product Number
Product Description

Ethyl alcohol, Pure, 200 proof, anhydrous, ≥99.5%
Ethyl alcohol, Pure, 190 proof, meets USP testing specifications
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Ethanol, anhydrous, denatured
Ethanol standards 10% (v/v), 10 % (v/v) in H2O, analytical standard
Ethanol Fixative 80% v/v, suitable for fixing solution (blood films)
MISSION® esiRNA, targeting human IL9R

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.